1. Home
  2. AKRO vs PRG Comparison

AKRO vs PRG Comparison

Compare AKRO & PRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • PRG
  • Stock Information
  • Founded
  • AKRO 2017
  • PRG 2020
  • Country
  • AKRO United States
  • PRG United States
  • Employees
  • AKRO N/A
  • PRG N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • PRG Diversified Commercial Services
  • Sector
  • AKRO Health Care
  • PRG Consumer Discretionary
  • Exchange
  • AKRO Nasdaq
  • PRG Nasdaq
  • Market Cap
  • AKRO 3.9B
  • PRG 1.1B
  • IPO Year
  • AKRO 2019
  • PRG N/A
  • Fundamental
  • Price
  • AKRO $51.77
  • PRG $30.52
  • Analyst Decision
  • AKRO Strong Buy
  • PRG Strong Buy
  • Analyst Count
  • AKRO 6
  • PRG 5
  • Target Price
  • AKRO $82.50
  • PRG $41.80
  • AVG Volume (30 Days)
  • AKRO 1.7M
  • PRG 386.2K
  • Earning Date
  • AKRO 08-08-2025
  • PRG 07-23-2025
  • Dividend Yield
  • AKRO N/A
  • PRG 1.70%
  • EPS Growth
  • AKRO N/A
  • PRG 99.08
  • EPS
  • AKRO N/A
  • PRG 4.90
  • Revenue
  • AKRO N/A
  • PRG $2,505,714,000.00
  • Revenue This Year
  • AKRO N/A
  • PRG $1.36
  • Revenue Next Year
  • AKRO N/A
  • PRG $4.29
  • P/E Ratio
  • AKRO N/A
  • PRG $6.23
  • Revenue Growth
  • AKRO N/A
  • PRG 4.62
  • 52 Week Low
  • AKRO $21.02
  • PRG $23.50
  • 52 Week High
  • AKRO $58.40
  • PRG $50.28
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 49.14
  • PRG 61.24
  • Support Level
  • AKRO $51.08
  • PRG $29.19
  • Resistance Level
  • AKRO $57.35
  • PRG $31.14
  • Average True Range (ATR)
  • AKRO 2.21
  • PRG 0.88
  • MACD
  • AKRO -0.81
  • PRG 0.15
  • Stochastic Oscillator
  • AKRO 11.08
  • PRG 84.30

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

Share on Social Networks: